Agenus Q1 net loss $26.4M ($1.03/sh); cash burn reduced; BOT/BAL 100% pCR in dMMR CRC

AGENUS INC

2025-Q1 EPS reported -$1.03 revenue$24,066,000

Q1 2025 cash $18.5M (down from $40.4M Dec 2024); operating cash burn $25.6M vs $38.2M YoY.
Net loss $26.4M ($1.03/sh) narrowed from $63.5M ($3.04/sh) Q1 2024; revenue $24.1M (non-cash royalty).
On track to cut annualized cash burn below $50M in H2 2025; final stages of collaboration for cash infusion.
BOT/BAL showed 100% pCR in dMMR CRC at higher dose; NEOASIS study responses in TNBC, sarcomas; HCC durable.
Appointed Dr. Richard Goldberg as Chief Development Officer to lead BOT/BAL regulatory engagement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.